Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2011, Vol. 31 Issue (9): 132-139    DOI:
    
Analysis of Global Status of Research, Development and Market on Stem Cell
FU Jun-ying
Institute of Scientific and Technical Information of China, Beijing 100038, China
Download: HTML   PDF(675KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Stem cell has become the global focus for its promising potential in research and practice. The governments, Institutes and enterprises all over the world have been increasing investment, and have made great progresses. Stem cell related papers and patents have sharply going up since 2001, and researches on clinic and pre-clinic trials became more and more though majority still focus on umbilical cord blood stem cells. USA remains the top position in all aspects in stem cell field. The numbers of stem cell related papers and patents produced by China are ranking top 10 around the world, but no Institute belongs to top one, and not many new products are developed successfully. China has to learn how to actively react to the changes resulted from related looser policy in USA.



Key wordsStem cell      Research      Development      Market     
Received: 07 April 2011      Published: 25 September 2011
ZTFLH:  Q813  
Cite this article:

FU Jun-ying. Analysis of Global Status of Research, Development and Market on Stem Cell. China Biotechnology, 2011, 31(9): 132-139.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2011/V31/I9/132


[1] Al-Tanbal H, Al Humaidan H, Al-Nounou R, et al. The value and practicality of granulocyte transfusion: a single oncology centre experience. Transfusion Medicine, 2010, 20(3): 160-168.

[2] 《中国组织工程研究与临床康复》杂志社学术部. 让昨天告诉今天:干细胞研究的学术与技术进展.中国组织工程研究与临床康复, 2009,13(6): 1102-1103. Academic Committee of Journal of Clinical Rehabilitative Tissue Engineering Research. Journal of Clinical Rehabilitative Tissue Engineering Research, 2009,13(6): 1102-1103.

[3] 石磊. 人类胚胎干细胞研究再起争议.世界科学, 2010,(10): 28-29. Shi L. World science, 2010,(10): 28-29.

[4] 朱宛宛,于洋,周琪.国际新格局下的干细胞研究发展与展望.学科发展,2009,24(3):284-289. Zhu W W, Yu Y, Zhou Q. Disciplinary Development, 2009,24(3):284-289.

[5] 李建明 曾华锋. 论科技政策背后的利益主体——以美国胚胎干细胞研究为例. 自然辩证法通讯, 2010,(5): 60-65. Li J W, Zeng H F. Journal of Dialectics of Nature, 2010,(5): 60-65.

[6] 江洪波,陈大明,于建荣.世界各国干细胞治疗相关政策与规划分析.生物产业技术,2009,(1):11-18. Jiang H B, Chen D M, Yu J R. Biotechnology & Business, 2009,(1):11-18.

[7] 李国炜,陈碧渊. 德国"干细胞法"及其述评. 医学与哲学, 2004,25(7): 76-77. Li G W, Chen B Y. Medicine & Philosophy, 2004,25(7): 76-77.

[8] Brian S,Melinda C,Amanda D,等. 英中印三国的干细胞战略. 生物技术世界, 2007,(2): 78-83. Brian S,Melinda C,Amanda D,et al. Biotechworld, 2007,(2): 78-83.

[9] 王静波.韩国生物技术的发展及其启示. 生物技术世界, 2006(2): 7-15. Wang J B. Biotechworld, 2006(2): 7-15.

[10] GBI Research. Stem Cell Research-Market Trends, Investment Trends and Pipeline Analysis. 2010.

[11] Strauss S. Geron trial resumes, but standards for stem cell trials remain elusive. Nature Biotechnology, 2010, 28(10): 989-990.

[1] WU Xiu-zhi,WANG Hong-jie,ZU Yao. Functional Study of hoxa1a Regulating Craniofacial Bone Development in Zebrafish[J]. China Biotechnology, 2021, 41(9): 20-26.
[2] ZHAO Xia,ZHU Zhe,ZU Yao. tbx2b Affects Atrioventricular Canal Development in Zebrafish[J]. China Biotechnology, 2021, 41(8): 1-7.
[3] QIAN Yu,DING Xiao-yu,LIU Zhi-qiang,YUAN Zeng-qiang. An Efficient Monoclonal Establishment Method of Genetically Modified Human Pluripotent Stem Cells[J]. China Biotechnology, 2021, 41(8): 33-41.
[4] LI Kai-xiu,SI Wei. Progress in the Treatment of Inflammatory Bowel Diseases by Exosomes Derived from Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(7): 66-73.
[5] WANG Yu-xuan,CHEN Ting,ZHANG Yong-liang. Research Progress on the Biological Function of MiR-148[J]. China Biotechnology, 2021, 41(7): 74-80.
[6] HE Wei,ZHU Lei,LIU Xin-ze,AN Xue-li,WAN Xiang-yuan. Research Progress on Maize Genetic Transformation and Commercial Development of Transgenic Maize[J]. China Biotechnology, 2021, 41(12): 13-23.
[7] WU Han-rong,WANG Ying,YANG Li,GE Yao,FAN Ling. Current Situation and Development Suggestions of China’s Biotechnology Base Platform[J]. China Biotechnology, 2021, 41(11): 119-123.
[8] WU Han-rong,WANG Ying,LI Su-ning,SANG Xiao-dong,FAN Ling. Policy Research on the Construction of Biotechnology Base Platforms in China[J]. China Biotechnology, 2021, 41(10): 127-131.
[9] ZHAO Jiu-mei,WANG Zhe,LI Xue-ying. Role of Signal Pathways and Related Factors Regulating Cartilage Formation in Bone Differentiation of Bone Marrow Mesenchymal Stem Cells[J]. China Biotechnology, 2021, 41(10): 62-72.
[10] MENG Xiao-lin,PANG Xi-ming,WANG Jie. Agrobacterium-mediated Transformation and the Functions of Pks in Marine-derived Penicillium oxalicum[J]. China Biotechnology, 2020, 40(9): 11-17.
[11] CHEN Fei,WANG Xiao-bing,XU Zeng-hui,QIAN Qi-jun. Molecular Mechanism and Clinical Research Progress of Mesenchymal Stem Cells in the Treatment of Diabetes Mellitus[J]. China Biotechnology, 2020, 40(7): 59-69.
[12] WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.
[13] DAI Qi-nan,ZHANG Jing-hong. Advances in Molecular Mechanisms Related to Tumor Multi-drug Resistance, Autophagy, DNA Repair and Tumor Stem Cells[J]. China Biotechnology, 2020, 40(4): 69-77.
[14] YUAN Ya-kun,LIU Guang-yang,LIU Yong-jun,XIE Ya-fang,WU Hao. Comparison of Research and Clinical Transformation on Mesenchymal Stem Cells between China and the US[J]. China Biotechnology, 2020, 40(4): 97-107.
[15] YANG Dan,TIAN Hai-shan,LI Xiao-kun. Research Progress of Fibroblast Growth Factor 5[J]. China Biotechnology, 2020, 40(3): 117-124.